



# BIOPRODUCTION **SUMMIT**

ADVANCES IN THERAPEUTIC PROTEIN PRODUCTION

## AGENDA - MONDAY, NOV 2, 2015

SESSION - I

### High Yielding Cell Line Development Platforms

7:30 Registration & Continental Breakfast

8:45 Chairman's Opening Remarks

**David Rabuka**

*Global Head of R&D, Chemical Biology at Catalent Pharma Solutions*

9:00 Optimization of Titer and a Specific Enzyme Conversion Step to Generate Fully Processed Antibody in CHO Cells

**Gregory T. Bleck, PhD**

*Global Head of R&D, Biologics, Catalent Pharma Solutions*

9:30 Celltheon SMART Expression Platform™ for stable long-term expression of next generation biologics and Biosimilar molecules.

**Amita Goel**

*Founder and CEO, Celltheon Corporation*

10:00 Switchable Membrane Reporter (SwiMR) technology for facile bioproduction and cell line development

**Bo Yu**

*Co-founder & CSO, Larix Bioscience*

10:30 To Fucosylate or Not: Utilizing FX Knockout CHO Lines to Express Fucosylated or Afucosylated Antibodies on Command

**Shahram Misaghi**

*Scientist, Cell Line Development, Genentech Inc.*

11:00 Exhibitors & Posters

11:45 Lunch

SESSION - II

### Genome Editing & CHO Cell Engineering

1:00 Chairman's Opening Remarks

**Bill Whitford**

*Senior Manager Cell Culture, GE Healthcare*

1:15 Tuning the CHO secretory pathway through a genome-scale systems biology approach

**Nathan E. Lewis**

*Assistant Professor, Department of Pediatrics, University of California, San Diego*

1:45 CHO cell engineering with CRISPR/Cas9, TARGATT™ integrase and beyond

**Dr. Ruby Yanru Chen-Tsai**

*PhD, Co-founder and Chief Scientific Officer, Applied StemCell, Inc.*

2:15 Rapid and Modular approaches to bio-production using a predictive high performance cell line expression platform

**Yemi Onakunle**

*Vice President, Business Development, Selexis SA*

2:45 Engineering Gene Sequences, Vector Elements and Strain Properties for Optimized mAb Production Yield in Mammalian Cell Lines

**Claes Gustafsson**

*Co-Founder, Chief Commercial Officer, DNA2.0 Inc*

3:15 Refreshment break/Exhibition Area

SESSION - III

### Process Development & Scale Up strategies

4:00 Chairman's Opening Remarks

**Sharif Ahmed**

*Associate Director Process Validation, Bayer Healthcare Pharmaceuticals*

4:10 Using a Multivariate Analysis Method to Assist in the Development of a Scale-Down Bioreactor Model

**Barry Wolf, Ph.D.**

*Principal Research Scientist, AbbVie/Biotherapeutics Inc*

4:40 Uses of Phenotype MicroArrays in Small Scale and High Throughput Bioprocess Improvement

**Barry Bochner**

*President, CEO and CSO, Biolog Inc.*

5:10 Process Development and Scale-Up Strategies Leading to Successful Process Validation

**Sharif Ahmed**

*Associate Director Process Validation, Bayer Healthcare Pharmaceuticals*

5:45 Networking Cocktail/ Exhibition Area